phrykt

Harvard Bioscience Inc (HBIO): who owns it and who trades it

As of Nov 16, 2026, HBIO insiders reported 5 purchases worth $202K in the last 12 months. The largest buyer was William Snider (Director), with $104K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Harvard Bioscience

From the latest filings

Overall: more buying than selling. Famous investors mostly sold. Insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, HBIO insiders reported $202K of open-market purchases and $0 of sales.

Purchases, 12 months
$202K
5 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Mar 17, 2026
Filed Mar 18, 2026

Purchases and sales by month

$202K$202KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Mar 17, 2026Stephen J DenelskyDirectorPurchase10,000$4.87$48.7KForm 4
Mar 17, 2026William SniderDirectorPurchase8,475$4.85$41.1KForm 4
Mar 16, 2026Mark T FrostCFOPurchase5,000$5.00$25KForm 4
Mar 16, 2026William SniderDirectorPurchase12,525$4.99$62.5KForm 4
Mar 16, 2026John D DukeCEOPurchase5,000$5.01$25.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
William SniderDirector$104K–Mar 17, 2026
Stephen J DenelskyDirector$48.7K–Mar 17, 2026
John D DukeChief Executive Officer, Director$25.1K–Mar 16, 2026
Mark T FrostChief Financial Officer$25K–Mar 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

HBIO short interest

Low short interest. 1.5% of HBIO shares are sold short: about 1 share in 68. Over the last 12 reports the number of shares short went down 45%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 66,461 HBIO shares were sold short, 1.5% of the shares outstanding, up 32.5% from the report before. At the average daily volume of 19,000 shares, buying them all back would take about 3.5 trading days (days to cover).

Shares short, % of all shares

1.46%May 15Oct 301.66%

Days to cover

3.5May 15Oct 305.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202666,4611.46%+32%19,0003.5
Oct 15, 202650,1611.10%+11%15,9293.1
Sep 30, 202644,9960.99%-7%17,2242.6
Sep 15, 202648,1461.06%-1%18,5722.6
Aug 31, 202648,5301.07%-18%22,0382.2
Aug 14, 202658,8271.29%-4%22,2492.6
Jul 31, 202661,3700.14%+10%11,5875.3
Jul 15, 202656,0150.13%-21%12,9094.3
Jun 30, 202670,8900.16%-21%16,6604.3
Jun 15, 202689,2500.20%-16%26,0433.4
May 29, 2026106,1970.24%-12%28,3453.8
May 15, 2026120,9330.27%-29%36,1333.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Harvard Bioscience company events

Harvard Bioscience filed 17 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, job cuts). The latest was on Nov 10, 2026.

  1. Nov 10, 2026AnnouncementShared information with investors. Filing
  2. Nov 10, 2026ResultsReleased financial results. Filing
  3. Aug 11, 2026AnnouncementShared information with investors. Filing
  4. Aug 11, 2026ResultsReleased financial results. Filing
  5. Jun 2, 2026LeadershipThe stockholders of Harvard Bioscience, Inc. voted to approve the Amended and Restated 2021 Incentive Plan at the Company’s 2026 Annual Meeting of Stockholders. Filing
  6. May 12, 2026AnnouncementShared information with investors. Filing
  7. May 12, 2026ResultsReleased financial results. Filing
  8. Mar 17, 2026AnnouncementShared information with investors. Filing
  9. Mar 12, 2026ResultsReleased financial results. Filing
  10. Mar 10, 2026LeadershipHarvard Bioscience, Inc. entered into an Amended and Restated Employment Agreement with John Duke, the Company’s Chief Executive Officer. Filing
  11. Mar 6, 2026AnnouncementFollowing stockholder approval of the Reverse Stock Split Proposal, the Board approved a final reverse stock split ratio of 1-for-10. Filing
  12. Feb 10, 2026ResultsReleased financial results. Filing
  13. Jan 29, 2026Job cutsAnnounced job cuts or other exit costs. Filing
  14. Jan 20, 2026RulesChanged its bylaws or articles. Filing
  15. Jan 12, 2026AnnouncementShared information with investors. Filing
  16. Dec 17, 2025LeadershipAs noted in Item 1.01 above, the Board has appointed Mr. William A. Snider as a member of the Board and the Compensation Committee of the Board, effective December 17, 2025. Filing
  17. Dec 5, 2025AnnouncementThe Company is engaged in ongoing discussions relating to its existing credit agreement, dated December 22, 2020, as amended, with Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company, and remains on track to complete the refinancing or repayment of the Credit… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Harvard Bioscience financials

Famous investors that hold HBIO

3 of the 50 well-known investors we track reported holding HBIO in their latest 13F filing. The largest position is Jim Simons's, worth $747K.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202694,327$747K0.0%-5%
Israel Englander · Millennium ManagementQ3 202627,060$214K0.0%-17%
Ken Griffin · Citadel AdvisorsQ3 202624,811$197K0.0%+87%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Harvard Bioscience Inc (HBIO) stock

Are HBIO insiders buying or selling?

In the last 12 months, HBIO insiders reported 5 open-market purchases worth $202K and no sales. The latest trade was on Mar 17, 2026. See every trade.

What is the short interest in HBIO?

As of Oct 30, 2026, 66,461 HBIO shares were sold short, 1.5% of the shares outstanding, up 32.5% from the report before. At the average daily volume of 19,000 shares, buying them all back would take about 3.5 trading days (days to cover). See the history.

Which famous investors hold HBIO?

3 of the 50 well-known investors we track reported HBIO in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $747K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.